Unique partnership brings new hope for vaccine to combat HIV

December 13, 2001

Imperial College and Chelsea and Westminster Healthcare NHS Trust will be at the heart of vital worldwide research into vaccines to combat HIV.

Thanks to a unique partnership with the International AIDS Vaccine Initiative (IAVI), the Trust is hosting a core laboratory, under the direction of Imperial College professor Frances Gotch, which will co-ordinate the evaluation of work from worldwide HIV/AIDS vaccine trials.

The laboratory is based at the St Stephen's Centre, Chelsea and Westminster Hospital, the largest HIV Unit in Europe, caring for nearly 4,000 patients.

The announcement comes on the day of The Diana International Lecture on AIDS held by National Aids Trust.

Diana, Princess of Wales, opened the renowned Kobler Clinic at the Stephen's Centre on September 13 1988. It was the first ever service designed for HIV patients.

IAVI is a global organisation working to speed the development and distribution of preventive AIDS vaccines - the world's best hope for ending the AIDS epidemic.

With Imperial College of Science, Technology and Medicine, and grants from US medical technology firm BD (Becton, Dickinson and Company; NYSE: BDX), IAVI has opened the laboratory to serve as a global clearinghouse for technical assistance to AIDS vaccine researchers worldwide.

The IAVI-Imperial College facility will work with vaccine development teams now or soon to be testing AIDS vaccine candidates in Kenya, Uganda, South Africa, India and China, as well as in the US and throughout Europe. The laboratory will provide equipment and instruction for running vaccine trials according to international standards.

In addition, the laboratory will assist technicians with performing the tests that determine whether an AIDS vaccine candidate is working as it is designed to. The laboratory will promote standardisation in these tests, to allow head-to-head evaluation of which vaccines work better than others.

Professor Frances Gotch, Professor of Immunology at Imperial College based at Chelsea and Westminster Hospital. She said: "It is excellent that IAVI has decided to support a core laboratory at Chelsea and Westminster Hospital.

"The urgency of the HIV epidemic demands that multiple vaccine designs are evaluated as soon as possible at many sites. Well validated and standardised modern technologies must be transferred to all vaccine sites and all evaluations need to be co-ordinated at a central site.

"We are honoured to have been chosen and feel that we have the experience and attributes necessary to carry out the task. Imperial College and Chelsea and Westminster Healthcare have a strong history of being at the forefront of clinical trials in this area."

AIDS now kills more people worldwide than any other infectious disease. More than 36.1 million people are living with HIV. Nearly all will die from AIDS-related complications within the next two decades. An estimated 5.3 million people were newly infected with HIV in 2000 (including almost 600,000 children).

"We hope our efforts will hasten the day when millions of young people in all parts of the world no longer have to face the inevitability of living and dying with HIV," said Professor Gotch.
For more information please contact:

Sarah McKellar at Chelsea and Westminster Hospital Press Office on 020 7761 1787 or Tom Miller at Imperial College Press Office on 020 7594 6704.

Notes to Editors:

1. Professor Gotch's expertise is in cellular immunology with the emphasis on investigations into the mechanisms and importance of T cell activity in disease. Professor Gotch is renowned for her research into vaccines for HIV/AIDS. She was instrumental in setting up a research laboratory in the Uganda Virus Research Institute, Entebbe, Uganda and will be responsible for supervising the Immunology Core Laboratory at Chelsea and Westminster Hospital.

2. Imperial College of Science, Technology and Medicine is the largest applied science, technology and medicine university institution in the UK. It is consistently rated in the top three UK university institutions for research quality, with one of the largest annual turnovers (UKP339 million in 1999-2000) and research incomes (UKP176 million in 1999-2000). Web site: www.ic.ac.uk

3. The laboratories at St Stephen's Centre, which are being leased to IAVI, are part of £3.6m redevelopment scheme at Chelsea and Westminster Hospital to develop HIV services and clinical research. This includes the refurbishment of the renowned Kobler Clinic and the construction of a new Clinical Research Centre which will open in the new year.

Imperial College London

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.